American Economic Journal: Applied Economics · 2023 · Mariana Carrera、Sofia Berto Villas‐Boas
中文摘要
通过在一家全国性零售商处实施的标签干预，我们检验了消费者对仿制药非处方药规避的三个假说：缺乏关于仿制药与品牌药可比性的信息、对其价格差异的疏忽，以及可通过同侪购买率信息降低的对仿制药质量的不确定性。采用双重差分策略，我们发现公布其他顾客购买情况的信息显著增加了仿制药购买份额，而其他处理的结果则好坏参半。先前未购买过仿制药的消费者似乎对该信息尤为敏感。这些发现对促进循证且具成本效益的选择具有政策启示。(JEL D12, D83, L65, L81, M37)
Abstract
Through a labeling intervention at a national retailer, we test three hypotheses for consumer aversion to generic over-the-counter drugs: lack of information on the comparability of generic and brand drugs, inattention to their price differences, and uncertainty about generic quality that can be reduced with information on peer purchase rates. With a difference-in-differences strategy, we find that posted information on the purchases of other customers increases generic purchase shares significantly, while other treatments have mixed results. Consumers without prior generic purchases appear particularly responsive to this information. These findings have policy implications for promoting evidence-based, cost-effective choices. (JEL D12, D83, L65, L81, M37)